Cooley advised Neurocrine, a leading biopharmaceutical company, on its agreement to acquire Soleno, a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases, for $2.9 billion.
Key deals, decisions + trends
Cooley advised Neurocrine, a leading biopharmaceutical company, on its agreement to acquire Soleno, a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases, for $2.9 billion.